AKR1B1 is considered a pharmacological target due to its role on diabetic inflammatory pathologies, overexpression in various types of cancer, and its role in promoting epithelial-mesenchymal transition (Banerjee and Turksen, 2021; Schwab et al., 2018). Here, AKR1B1 is linked to cancer.